Physician profile
Brooke E Harden
NPI 1821280124
$388.32
in general payments reported to CMS, 2019-2025
9 companies · $88.42 in 2025
The $88.42 reported for 2025 was more than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $87.25 · 2024: $213 · 2025: $88.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $69.28 | 2024-2025 | Entyvio |
| Braintree Laboratories, INC. | $61.95 | 2023-2024 | Sutab, Suflave |
| Qol Medical, LLC | $59.28 | 2023-2024 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $47.12 | 2024-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.53 | 2024-2025 | Xifaxan, Relistor |
| Aimmune Therapeutics, INC. | $31.98 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $31.37 | 2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $24.07 | 2025 | Voquezna |
| Fresenius Kabi USA, LLC | $20.74 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Harden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.